TScan Therapeutics (TCRX) Common Equity (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Common Equity data on file, last reported at $96.9 million in Q1 2026.

• On a quarterly basis, Common Equity fell 53.89% year-over-year to $96.9 million in Q1 2026; TTM through Mar 2026 was $96.9 million, a 53.89% decrease from a year earlier, with the FY2025 full-year figure at $123.1 million, down 48.91% from the prior year.
• Common Equity for Q1 2026 stood at $96.9 million, down from $123.1 million in the prior quarter.
• Over the last five years, Common Equity for TCRX reached as high as $255.2 million in Q2 2024 and fell as low as $78.0 million in Q1 2023.
• Historically, Common Equity has averaged $157.7 million across 5 years, with a median of $145.7 million in 2022.
• Across the five-year window, Common Equity jumped 391.84% in 2022 and sank 53.89% in 2026, its largest moves.
• Year by year, Common Equity stood at $99.4 million in 2022, then jumped by 51.73% to $150.9 million in 2023, then soared by 59.72% to $241.0 million in 2024, then slumped by 48.91% to $123.1 million in 2025, then retreated by 21.28% to $96.9 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $96.9 million in Q1 2026, $123.1 million in Q4 2025, and $144.0 million in Q3 2025.